Mechanisms of cancer treatment by radiotherapy combined with immune
checkpoint blockade

doi:10.3760/cma.j.issn.1673422X.2017.03.013

Abstract

Abstract: With the further researches on the immune mechanisms in tumor, more and more scholars notice the phenomenon that radiation activates the immunity, and find that "radiotherapy causes immunity suppression" is onesided. Although body′s antitumor immunity can be enhanced by radiotherapy, in clinical, we observe that patients who receive radiotherapy cannot avoid tumor recurrence and metastasis. Researches show that tumor microenvironment makes the immune checkpoint pathway abnormally activated. Therefore, the combination of radiotherapy and immune checkpoint inhibitor can change the tumor microenvironment, and can improve the therapeutic effect.

Key words: Radiotherapy, Tumor escape, Immune checkpoint blockade

Chen Zehong, Su Ruxiong, Yang Zike, Kang Shijun. Mechanisms of cancer treatment by radiotherapy combined with immune checkpoint blockade[J]. Journal of International Oncology, 2017, 44(3): 209-212.

References

［1］ HerterSprie GS, Koyama S, Korideck H, et al. Synergy of radiotherapy and PD1 blockade in Krasmutant lung cancer［J］. JCI Insight, 2016, 1(9): e87415. ［2］ McNutt M. Cancer immunotherapy［J］. Science, 2013, 342(6165): 1417. DOI: 10.1126/science.1249481. ［3］ Shiao SL, Ruffell B, Denardo DG, et al. TH2polarized CD4(+) T cells and macrophages limit efficacy of radiotherapy［J］. Cancer Immunol Res, 2015, 3(5): 518-525. DOI: 10.1158/23266066.CIR140232. ［4］ Levy A, Chargari C, Marabelle AA, et al. Can immunostimulatory agents enhance the abscopal effect of radiotherapy?［J］. Eur J Cancer, 2016, 62: 36-45. DOI: 10.1016/j.ejca.2016.03.067. ［5］ Reynders K, Illidge T, Siva S, et al. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant［J］. Cancer Treat Rev, 2015, 41(6): 503-510. DOI: 10.1016/j.ctrv.2015.03.011. ［6］ Formenti SC, Demaria S. Systemic effects of local radiotherapy［J］. Lancet Oncol, 2009, 10(7): 718-726. DOI: 10.1016/S14702045(09)700828. ［7］ Bos PD, Plitas G, Rudra D, et al. Transient regulatory T cell ablation deters oncogenedriven breast cancer and enhances radiotherapy［J ］. J Exp Med, 2013, 210(11): 2435-2466. DOI: 10.1084/jem.20130762. ［8］ Zeng J, See AP, Phallen J, et al. AntiPD1 blockade and stereotactic radiation produce longterm survival in mice with intracranial gliomas［J］. Int J Radiat Oncol Biol Phys, 2013, 86(2): 343- 349. DOI: 10.1016/j.ijrobp.2012.12.025. ［9］ Scheithauer H, Belka C, Lauber K, et al. Immunological aspects of radiotherapy［J］. Radiat Oncol, 2014, 9: 185. DOI: 10.1186/1748717X9 185. ［10］ Weiss EM, Wunderlich R, Ebel N, et al. Selected antitumor vaccines merit a place in multimodal tumor therapies［J］. Front Oncol, 2012, 2: 132. DOI: 10.3389/fonc.2012.00132. ［11］ Green DR, Ferguson T, Zitvogel LA. Immunogenic and tolerogenic cell death［J］. Nat Rev Immunol, 2009, 9(5): 353363. DOI: 10.1038/nri2545. ［12］ Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity［J］. Cell, 2010, 140(6): 798-804. DOI: 10.1016/j.cell.2010.02.015. ［13］ Tang C, Wang XH, Soh H, et al. Combining radiation and immunotherapy: a new systemic therapy for solid tumors?［J］. Cancer Immunol Res, 2014, 2(9): 831-838. DOI: 10.1158/23266066.CIR140069. ［14］ Matsumura S, Wang B, Kawashima N, et al. Radiationinduced CXCL16 release by breast cancer cells attracts effector T cells［J］. J Immunol, 2008, 181(5): 3099-3107. ［15］ Pilones KA, VanpouilleBox C, Demaria S. Combination of radiotherapy and immune checkpoint inhibitors［J］. Semin Radiat Oncol, 2015, 25(1): 28-33. DOI: 10.1016/j.semradonc.2014.07.004. ［16］ Marincola FM, Jaffee EM, Hicklin DJ, et al. Escape of human solid tumors from Tcell recognition: molecular mechanisms and functional significance［J］. Adv Immunol, 2000, 74: 181-273. ［17］ Apetoh L, Ghiringhelli F, Tesniere AA, et al. Tolllike receptor 4 dependent contribution of the immune system to anticancer chemotherapy and radiotherapy［J］. Nat Med, 2007, 13(9): 1050-1059. DOI: 10.1038/nm1622. ［18］ Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class Ⅰ expression, and induces successful antitumor immunotherapy［J］. J Exp Med, 2006, 203(5): 1259-1271. DOI: 10.1084/jem.20052494. ［19］ Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift［J］. J Natl Cancer Inst, 2013, 105(4): 256 -265. DOI: 10.1093/jnci/djs629. ［20］ Bumette B, Weichselbaum RR. The immunology of ablative radiation［J ］. Semin Radiat Oncol, 2015, 25(1): 40-45. DOI: 10.1016/j.semradonc.2014.07.009. ［21］ RodriguezRuiz ME, Rodriguez I, Garasa SA, et al. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming［J］. Cancer Res, 2016, 76(20): 5994-6005. DOI: 10.1158/00085472.CAN160549. ［22］ Mole RH. Whole body irradiation; radiobiology or medicine?［J］. Br J Radiol, 1953, 26(305): 234-241. ［23］ Kalbasi A, June CH, Haas N, et al. Radiation and immunotherapy: a synergistic combination［J］. J Clin Invest, 2013, 123(7): 2756-2763. DOI: 10.1172/JCI69219. ［24］ Gabrilovich DI, OstrandRosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours［J］. Nat Rev Immunol, 2012, 12(4): 253-268. DOI: 10.1038/nri3175. ［25］ Deng L, Liang H, Burnette B, et al. Irradiation and antiPDL1 treatment synergistically promote antitumor immunity in mice［J］. J Clin Invest, 2014, 124(2): 687-695. DOI: 10.1172/JCI67313. ［26］ Park SS, Dong HD, Liu X, et al. PD1 restrains radiotherapyinduced abscopal effect［J］. Cancer Immunol Res, 2015, 3(6): 610-619. DOI: 10.1158/23266066.CIR140138. ［27］ Demaria S, Kawashima N, Yang AM, et al. Immunemediated inhibition of metastases after treatment with local radiation and CTLA4 blockade in a mouse model of breast cancer［J］. Clin Cancer Res, 2005, 11(2 Pt 1): 728 -734.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[5]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[6]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[7]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[8]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[9]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[10]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association. Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version） [J]. Journal of International Oncology, 2023, 50(4): 193-201.
[11]	Li Jun, Xue Sheng, Wang Weijie, Tao Run, Zhang Jiajun. Expression of TPX2 in kidney renal clear cell carcinoma and its clinical significance [J]. Journal of International Oncology, 2023, 50(4): 214-219.
[12]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng. Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance [J]. Journal of International Oncology, 2023, 50(4): 227-230.
[13]	Shi Xaioqi, Wang Hongyan. Research progress on the interaction between gut microbiota and radiation enteritis [J]. Journal of International Oncology, 2023, 50(4): 244-247.
[14]	Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun. Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases [J]. Journal of International Oncology, 2023, 50(3): 138-143.
[15]	Huang Huayu, Gong Hongyun, Song Qibin. Influencing factors of pneumonitis in the period of thoracic radiotherapy combined with immunotherapy [J]. Journal of International Oncology, 2023, 50(2): 102-106.

Mechanisms of cancer treatment by radiotherapy combined with immune checkpoint blockade

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments